Investors seeking early exposure to cutting-edge life sciences companies will have a direct line to management teams at the Life Sciences Virtual Investor Forum on September 17, 2026. Hosted by Virtual Investor Conferences and marketed by B2i Digital, Inc., the online event features 30-minute live presentations and Q&A sessions from seven companies developing therapies in oncology, fibrosis, drug delivery, antibiotics, cannabinoid therapeutics, and respiratory imaging. The forum matters because it offers a rare opportunity to hear directly from executives about pipeline progress and strategic priorities, bypassing the often dry reading of filings. As David Shapiro, CEO of B2i Digital, noted, “Reading company filings is a great cure for insomnia, but if you want to stay awake and hear it directly from management, these conferences are the best way to get a real feel for the company.”
The lineup includes Sona Nanotech Inc., which is advancing a photothermal cancer therapy built on gold nanorods; Raphael Pharmaceutical, focused on cannabinoid-based formulations for rheumatoid arthritis, chronic lung inflammation, and autoimmune disease; and Amplia Therapeutics Ltd., developing a pipeline of Focal Adhesion Kinase inhibitors for cancer and fibrosis. Adaptin Bio, Inc. will present precision drug delivery technologies aimed at target tissues, including behind the blood-brain barrier, while Acurx Pharmaceuticals, Inc. is working on a new class of antibiotics for infections caused by bacteria listed as priority pathogens. CytoDyn Inc. brings a humanized monoclonal antibody being studied in solid-tumor oncology, and 4DMedical Ltd. offers FDA-cleared four-dimensional respiratory imaging. The diversity of these approaches underscores the breadth of innovation in life sciences, from novel cancer treatments to addressing antimicrobial resistance.
For investors, the implications are significant. These companies operate in high-risk, high-reward areas where clinical milestones can dramatically impact valuations. The forum provides a platform for management to articulate their vision and answer unscripted questions, which can reveal insights not found in press releases. Replays will be available on the B2i Digital and OTC Markets YouTube channels, extending access beyond the live event. Registration and event details are available at https://b2idigital.com/sept-17-life-sciences-virtual-investor-forum.
The event is part of a broader trend of virtual investor conferences that connect public companies with a global audience. Virtual Investor Conferences, an OTC Markets Group Inc. property, regularly features companies from major exchanges worldwide. B2i Digital’s role as marketing partner leverages its extensive media network, which spans over 800 outlets and reaches millions of investors monthly. This collaboration aims to elevate the profile of presenting companies, potentially increasing liquidity and analyst coverage. As the life sciences sector continues to evolve, forums like this serve as a critical bridge between innovative science and the capital needed to bring therapies to market. Investors who attend may gain a competitive edge by understanding the science and strategy behind each company’s approach.
